-
Mashup Score: 2Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors - 3 day(s) ago
Recently, the advent of rearranged during transfection (RET)-selective inhibitors has revolutionized the management of RET-altered cancers.1 Whereas genetically altered RET kinases drive oncogenesis, the wild-type RET is activated by growth and differentiation factor 15 (GDF15) via its binding to the RET coreceptor GDNF family receptor α-like (GFRAL) located at the appetite control centers in the hindbrain. The GDF15–GFRAL–RET axis has been preclinically shown to regulate anorexia and cachexia that cause body weight loss.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 23T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC - 4 day(s) ago
Trastuzumab deruxtecan plus pembrolizumab showed early efficacy in patients with IO-naive, HER2-expressing or -mutant non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet-
T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC https://t.co/SDzJOIPew8 via @onclive
-
-
Mashup Score: 19
Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a slideshow.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet-
Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies https://t.co/udgkn0VF2D via @onclive
-
-
Mashup Score: 8
The approval of this combination is supported by data from the phase 3 CodeBreaK 300 study.
Source: www.targetedonc.comCategories: General Medicine News, Hem/OncsTweet-
FDA Oks Sotorasib/Panitumumab in KRAS G12C-Mutant Colorectal Cancer https://t.co/Z5LeM0zw8J via @targetedonc
-
-
Mashup Score: 23T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC - 5 day(s) ago
Trastuzumab deruxtecan plus pembrolizumab showed early efficacy in patients with IO-naive, HER2-expressing or -mutant non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet-
T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC https://t.co/SDzJOIPew8 via @onclive
-
-
Mashup Score: 19
Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a slideshow.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet-
Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies https://t.co/udgkn0VF2D via @onclive
-
-
Mashup Score: 8Artificial Intelligence–Guided Lung Ultrasound by Nonexperts - 6 day(s) ago
This multicenter validation study evaluates the ability of artificial intelligence to guide acquisition of diagnostic-quality lung ultrasound images by trained health care professionals.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
Artificial Intelligence–Guided Lung Ultrasound by Nonexperts https://t.co/iqOqewxRAv
-
-
Mashup Score: 41
The FDA has approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult solid tumor nivolumab (Opdivo) indications.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet-
🚨It’s Friday & we have another FDA approval 👉🏼FDA Approves Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors https://t.co/Dt5ut8QfdD via @onclive
-
-
Mashup Score: 17Genetic Ancestry–Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies - 7 day(s) ago
This cohort study examines if the approval of precision oncology therapies has benefited patients with cancer from various ancestral backgrounds equally over time.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
Genetic Ancestry–Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies https://t.co/H3bCoxzWUj
-
-
Mashup Score: 20After Being Evacuated amid L.A. Fires, Doctor's Family Follows Him to Hospital to Help Cancer Patients: 'We're Not Going to Leave You' - 8 day(s) ago
Dr. Ravi Salgia is an oncologist at City of Hope cancer center. When he and his wife and adult daughter were evacuated from their Pasadena home due to the fires, they followed him to the hospital to help patients.
Source: PEOPLE.comCategories: General Medicine News, Hem/OncsTweet-
Link to article : L.A. Oncologist's Family Is Evacuated, Follows Him to Hospital to Help @Aiims1742 @acmoorephd @cityofhope @oncodaily https://t.co/HiBXtOlTA0
-
@acmoorephd Clinically we observed weight gain 👉🏼Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors @Annals_Oncology https://t.co/cGj934PgeR